| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $42,910,623 | 26 | 100 |
| Waddill William D. | director | 0 | $0 | 1 | $566,038 | $-566,038 |
| Vakiener Victoria | director | 0 | $0 | 1 | $679,491 | $-679,491 |
| OLUKOTUN ADEOYE Y | director | 0 | $0 | 2 | $696,762 | $-696,762 |
| PERRY MICHAEL S | director | 0 | $0 | 1 | $991,738 | $-991,738 |
| Ferrari Mauro | director | 0 | $0 | 2 | $1.02M | $-1.02M |
| O'Brien Patrick | COO | 0 | $0 | 1 | $3.12M | $-3.12M |
| Hamilton James C | Chief Medical Officer | 0 | $0 | 6 | $4.26M | $-4.26M |
| Anzalone Christopher Richard | Chief Executive Officer | 0 | $0 | 13 | $31.59M | $-31.59M |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $0 and sold $42.91M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $63,231 and sold $20.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
| 2026-01-05 | Sale | O'Brien Patrick | COO | 49,493 0.0354% | $63.11 | $3.12M | +5.97% | |
| 2026-01-05 | Sale | Hamilton James C | Chief Medical Officer | 40,164 0.0287% | $63.11 | $2.53M | +5.97% | |
| 2026-01-02 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 13,187 0.0095% | $66.10 | $871,703 | -2.22% | |
| 2025-12-29 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 51,726 0.0369% | $69.13 | $3.58M | -4.00% | |
| 2025-12-26 | Sale | Ferrari Mauro | director | 7,530 0.0054% | $70.00 | $527,100 | -4.59% | |
| 2025-12-22 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 12,586 0.009% | $68.44 | $861,340 | -2.80% | |
| 2025-12-19 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 13,445 0.0097% | $67.66 | $909,683 | -1.47% | |
| 2025-12-19 | Sale | Waddill William D. | director | 8,367 0.006% | $67.65 | $566,038 | -1.47% | |
| 2025-12-19 | Sale | Vakiener Victoria | director | 10,040 0.0072% | $67.68 | $679,491 | -1.47% | |
| 2025-12-19 | Sale | OLUKOTUN ADEOYE Y | director | 10,000 0.0072% | $67.66 | $676,623 | -1.47% | |
| 2025-12-17 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 85,000 0.0608% | $64.04 | $5.44M | +3.64% | |
| 2025-12-16 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 54,298 0.0359% | $62.58 | $3.4M | +3.73% | |
| 2025-12-15 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 130,000 0.0946% | $68.85 | $8.95M | -2.04% | |
| 2025-12-05 | Sale | PERRY MICHAEL S | director | 16,250 0.0117% | $61.03 | $991,738 | +10.64% | |
| 2025-11-28 | Sale | Ferrari Mauro | director | 8,750 0.0068% | $56.39 | $493,413 | +27.27% | |
| 2025-10-01 | Sale | Hamilton James C | Chief Medical Officer | 20,000 0.0147% | $35.00 | $700,000 | +42.09% | |
| 2025-09-12 | Sale | Hamilton James C | Chief Medical Officer | 15,000 0.011% | $30.00 | $450,000 | +38.83% | |
| 2025-09-02 | Sale | Hamilton James C | Chief Medical Officer | 15,000 0.0106% | $25.00 | $375,000 | +56.97% | |
| 2025-08-15 | Sale | Hamilton James C | Chief Medical Officer | 9,389 0.0066% | $20.00 | $187,780 | +92.95% | |
| 2025-08-13 | Sale | Hamilton James C | Chief Medical Officer | 611 0.0004% | $20.00 | $12,220 | +97.67% |
| Anzalone Christopher Richard | Chief Executive Officer | 3792739 2.7912% | $254.3M | 4 | 51 | <0.0001% |
| O'Brien Patrick | COO | 474908 0.3495% | $31.84M | 0 | 14 | |
| Hamilton James C | Chief Medical Officer | 171958 0.1266% | $11.53M | 0 | 19 | |
| PERRY MICHAEL S | director | 115240 0.0848% | $7.73M | 0 | 6 | |
| Ferrari Mauro | director | 69053 0.0508% | $4.63M | 2 | 6 | +71% |
| Waddill William D. | director | 56563 0.0416% | $3.79M | 0 | 10 | |
| Vakiener Victoria | director | 35723 0.0263% | $2.4M | 0 | 5 | |
| OLUKOTUN ADEOYE Y | director | 33600 0.0247% | $2.25M | 0 | 6 | |
| GIVEN BRUCE D | Chief Operating Officer | 850730 0.6261% | $57.04M | 0 | 19 | |
| Myszkowski Kenneth Allen | Chief Financial Officer | 455433 0.3352% | $30.54M | 1 | 29 | <0.0001% |
| Li Zhen | Snr. VP, Chem and Non-Clin Dev | 201700 0.1484% | $13.52M | 0 | 1 | |
| San Martin Javier | Chief Medical Officer | 198497 0.1461% | $13.31M | 0 | 5 | |
| KNOTT DAVID M | 10 percent owner | 166778 0.1227% | $11.18M | 1 | 3 | <0.0001% |
| Leone Peter Brian | VP, Strategic Bus. Initiatives | 130000 0.0957% | $8.72M | 0 | 1 | |
| Oliver Tracie | Chief Commercial Officer | 127107 0.0935% | $8.52M | 0 | 3 | |
| GIVEN DOUGLAS B | director | 124167 0.0914% | $8.33M | 1 | 21 | <0.0001% |
| Hassard James | Chief Commercial Officer | 105750 0.0778% | $7.09M | 0 | 2 | |
| Lu Hongbo | director | 33680 0.0248% | $2.26M | 3 | 0 | <0.0001% |
| FRYKMAN EDWARD W | director | 23852 0.0176% | $1.6M | 0 | 1 | |
| McKenney Charles | director | 17220 0.0127% | $1.15M | 1 | 16 | |
| De Backer Marianne | director | 17000 0.0125% | $1.14M | 9 | 2 | +50.28% |
| Kingsley Joseph Theodore III | Interim President & CFO | 12000 0.0088% | $804,600.00 | 2 | 0 | +27.7% |
| Ching Marshall Robert | 10 percent owner | 0 0% | $0 | 0 | 6 | |
| Lewis David L. | Chief Scientific Officer | 0 0% | $0 | 0 | 3 | |
| Bradshaw Curt | Chief Scientific Officer | 0 0% | $0 | 0 | 2 |
$211,610,344 | 91 | 38.45% | $10.91B | |
$2,765,836 | 72 | 20.00% | $10.8B | |
$108,876,545 | 67 | 72.81% | $8.14B | |
$88,307,390 | 38 | -1.70% | $10.25B | |
$19,233,721 | 36 | 70.14% | $11.87B | |
Arrowhead Pharmaceuticals, Inc. (ARWR) | $1,801,511 | 23 | 18.58% | $9.11B |
$103,944,213 | 17 | 5.95% | $6.87B | |
$11,859,102 | 17 | 18.62% | $7.75B | |
$1,279,017 | 16 | 51.12% | $9.37B | |
$627,701,115 | 15 | 145.68% | $12.28B | |
$57,686,748 | 13 | 21.11% | $6.04B | |
$9,976,473 | 12 | 29.52% | $6.59B | |
$284,820 | 10 | 45.67% | $13B | |
$11,898,979 | 10 | 54.58% | $8.16B | |
$948,235 | 8 | 15.56% | $10.62B | |
$55,713,031 | 8 | -0.36% | $6.35B | |
$105,414,951 | 5 | 10.07% | $7.74B | |
$41,376,000 | 4 | -12.07% | $6.9B | |
$36,900,000 | 3 | -9.12% | $10.94B |
| Increased Positions | 175 | +57% | 16M | +14.65% |
| Decreased Positions | 129 | -42.02% | 9M | -8.26% |
| New Positions | 72 | New | 6M | New |
| Sold Out Positions | 40 | Sold Out | 2M | Sold Out |
| Total Postitions | 353 | +14.98% | 114M | +6.39% |
| Blackrock, Inc. | $1.37M | 14.87% | 20.22M | +799,938 | +4.12% | 2025-09-30 |
| Vanguard Group Inc | $1.09M | 11.79% | 16.04M | +510,798 | +3.29% | 2025-09-30 |
| Avoro Capital Advisors Llc | $738,911.00 | 8.02% | 10.9M | +300,000 | +2.83% | 2025-09-30 |
| State Street Corp | $433,677.00 | 4.7% | 6.4M | +26,308 | +0.41% | 2025-09-30 |
| Fmr Llc | $390,459.00 | 4.24% | 5.76M | +589,520 | +11.4% | 2025-09-30 |
| Slate Path Capital Lp | $337,730.00 | 3.66% | 4.98M | -250,000 | -4.78% | 2025-09-30 |
| Geode Capital Management, Llc | $212,253.00 | 2.3% | 3.13M | +152,537 | +5.12% | 2025-09-30 |
| Siren, L.L.C. | $180,991.00 | 1.96% | 2.67M | 0 | 0% | 2025-09-30 |
| Driehaus Capital Management Llc | $142,318.00 | 1.54% | 2.1M | +2M | New | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $141,118.00 | 1.53% | 2.08M | +2M | +3,142.51% | 2025-09-30 |